Drugs · acquisition-cost intelligence
budesonide
· ingredient budesonideCorticosteroids· BUDESONIDE 2 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$9.31
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other budesonide products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| budesonide | $0.52084 | −$8.79 |
| Budesonide Inhalation Suspension | $0.69110 | −$8.62 |
| Budesonide Inhalation | $0.72986 | −$8.58 |
| Budesonide Inhalation Suspension | $0.76862 | −$8.54 |
| Budesonide | $1.39 | −$7.92 |
| Uceris | $11.99 | +$2.68 |
| BREYNA | $19.78 | +$10.47 |
Medicare Part D coverage · CY2026
On 73 plan formularies · typical tier 1
Prior auth 8% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.